ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2969

X-Ray Diffraction of Spontaneously Draining Calcinosis in Patients with Scleroderma

Vivien Hsu1, Thomas Emge2 and Naomi Schlesinger3, 1Medicine, Rutgers University, New Brunswick, NJ, 2Dept of Chemistry and Chemical Biology, Rutgers- the State University, Piscataway, NJ, 3Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Calcinosis and scleroderma

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Calcinosis is caused by deposition of calcified materials in the soft tissues (1). Hydroxyapatite (HA) is reported to be its major constituent (2).  Mechanical stress and local tissue hypoxia are believed to be important in its pathogenesis (3).  Our aim was to analyze spontaneously draining material from calcinosis sites in scleroderma (SSc) patients using x-ray diffraction.

Methods: In this IRB-approved study, we enrolled SSc patients meeting the American College of Rheumatology criteria for definite SSc (4).  Pertinent clinical data was collected.  Xray diffraction data were used to determine solid phase present (e.g., HA versus other Ca phosphate phase) and to approximate the % amorphous and % crystalline components using a Bruker HiStar multi-wire area detector.

Results: Ten female subjects (see Table 1) with advanced SSc were enrolled with mean disease duration 16 years; 6 had diffuse SSc.  Calcinosis occurred later in the disease course and 7 had extensive calcinosis affecting multiple sites.  Draining calcinosis was collected from multiple sites, most commonly the hand.  X-ray diffraction confirmed HA of varying percentages in all but one specimen.  Solid samples generally contained higher amounts of HA.  

Conclusion: By using x-ray diffraction, our study corroborates previous published reports (2, 3) that HA crystal deposition is the main constitute of SSc-related calcinosis.  Solid samples contained higher amounts of HA crystals; fluid samples observed by optical microscopy to contain solids, including HA in suspension.   Further research is needed to characterize the amorphous materials associated with HA deposition in SSc patients with calcinosis.  

Table 1: SSc clinical characteristics and crystal analysis:

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

  

   

   

   

   

   

   

   

  

Patient #
   

SSc     type
   

SSc/

calcinosis     onset (in years)
   

Auto-antibodies
   

sites
   

State
   

Crystalline    

component
   

1
   

D*
   

15/9
   

ANA/Nucleolar/
   

Scl70
   

elbow  thigh groin
   

liquid*
   

liquid
   

liquid
   

HA** (25%)
   

HA (20%)
   

HA (20%)
   

 
   

2
   

D
   

19/9
   

ANA/Scl70
   

belly
   

liquid
   

HA (3%)
   

 
   

3
   

L**
   

15/3
   

ANA/ACA
   

groin
   

liquid
   

HA (2%)
   

4
   

L
   

19/5
   

ANA/ACA/RNP
   

finger
   

liquid
   

HA (8%)
   

 
   

5
   

L
   

16/3
   

ANA
   

Elbow over
   

3 days
   

solid 
   

liquid
   

solid
   

HA (40%)
   

HA (40%)
   

HA (4%)
   

 
   

6
   

D
   

14/3
   

Scl70/RNApol3
   

finger
   

solid
   

HA (15%)
   

 
   

7
   

D
   

11/9
   

Scl70
   

finger over
   

3 days
   

solid
   

liquid
   

liquid
   

HA (50%)
   

HA (7%)
   

HA (10%)
   

 
   

8
   

D
   

9/4
   

Scl70/ANA
   

shoulder
   

Solid     mass
   

HA (3%)
   

 
   

9
   

L
   

29/4
   

ANA/RNApol3/
   

nucleolar
   

Belly
   

 

finger
   

Solid***

solid

 
   

calcite (<1%)
   

HA (2%)
   

10
   

D
   

10/2
   

ANA
   

finger
   

solid
   

HA (43%)
   

*Diffuse   **Limited

References

  1. Steen et al Arthritis Rheum 1984; 27:125.
  2. Leroux et al. J Rheumatol 1983; 10:242.
  3. Davies et al.  Rheumatology 2009; 48:876.
  4. Hoogen et al., Ann Rheum Dis 2013;72:1747 & Arthritis Rheum 2013;65(11):2737-57.

Disclosure: V. Hsu, None; T. Emge, None; N. Schlesinger, Novartis Pharmaceutical Corporation, 2,Takeda, novartis, 8,Novartis, Astra Zeneca, Pfizer, 5.

To cite this abstract in AMA style:

Hsu V, Emge T, Schlesinger N. X-Ray Diffraction of Spontaneously Draining Calcinosis in Patients with Scleroderma [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/x-ray-diffraction-of-spontaneously-draining-calcinosis-in-patients-with-scleroderma/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/x-ray-diffraction-of-spontaneously-draining-calcinosis-in-patients-with-scleroderma/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology